Vitalhub stock analysis
Vitalhub (VHIBF) Stock Price & Analysis
VHIBF Stock Chart & Stats
- Day’s Range
- $4.58 - $4.79
- 52-Week Range
- $4.57 - $7.06
- Previous Close
- $4.61
- Volume
- N/A
- Average Volume (3M)
- 23.00K
- Market Cap
- $310.99M
- Enterprise Value
- $359.75M
- Total Cash (Recent Filing)
- $129.01M
- Total Debt (Recent Filing)
- $3.22M
- Price to Earnings (P/E)
- 40.2
- Beta
- 0.90
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Growth
Strong ARR and recurring-revenue growth supports greater visibility than project-based sales alone. A larger contracted revenue base can improve retention economics, stabilize planning, and provide a durable platform for cross-selling additional healthcare workflow and care-coordination products.
Margin Improvement
The higher adjusted EBITDA margin indicates meaningful operating leverage and improving profitability as Vitalhub integrates acquisitions and manages development spending. Sustaining this margin would strengthen internal funding capacity and make future growth less dependent on external capital.
Debt-Free Balance Sheet
A debt-free balance sheet with substantial cash gives Vitalhub financial flexibility to absorb operating variability, invest in its software platform, and pursue complementary acquisitions. Low leverage also reduces interest burden and preserves strategic options through changing healthcare technology conditions.
Bears Say
SHREWD Customer Uncertainty
The SHREWD situation creates a material risk to recurring revenue durability because management cannot yet determine which accounts may be affected. Continued suspensions or reversals could reduce ARR, delay growth recovery, and require the broader portfolio to offset a meaningful product-specific shortfall.
Revenue Growth Slowdown
The recent revenue slowdown challenges the durability of Vitalhub's earlier growth trajectory, even as recurring revenue expands. Flat total revenue and weaker variable revenue can limit near-term operating leverage, complicate forecasting, and increase reliance on successful renewals, integrations, and new bookings.
Attend Anywhere Decline
A potential continuing decline in Attend Anywhere represents a structural product-level headwind within the portfolio. Even if other offerings offset part of the reduction, lower renewals or usage can weigh on recurring revenue, reduce cross-product momentum, and increase the execution burden on newer growth initiatives.
Vitalhub News
VHIBF FAQ
What was Vitalhub’s price range in the past 12 months?
What is Vitalhub’s market cap?
When is Vitalhub’s upcoming earnings report date?
How were Vitalhub’s earnings last quarter?
Is Vitalhub overvalued?
Does Vitalhub pay dividends?
What is Vitalhub’s EPS estimate?
How many shares outstanding does Vitalhub have?
What happened to Vitalhub’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vitalhub?
What is the TipRanks Smart Score and how is it calculated?
Vitalhub Stock Smart Score
Company Description
Vitalhub
Vitalhub Corp., through its subsidiaries, provides innovative technological solutions to health and human service providers internationally, specifically catering to markets in Canada, the United States, the United Kingdom, Australia, and Western Asia. The company's diverse array of offerings comprises electronic healthcare records, case management systems, care coordination platforms, tools for optimizing patient flow and operational insights, and various mobile applications. Incorporated in 2010, Vitalhub is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Daniel Paul Matlow
- Employees
- 700
- Website
- vitalhub.com
- Address
- 480 University Avenue, Toronto, ON, M5G 1V2, CA
Vitalhub (VHIBF) Earnings & Revenues
VHIBF Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 14% ARR growth, 9% recurring revenue growth, a two-year-high 27% adjusted EBITDA margin, a return to net income, 69% growth in year-to-date operating cash flow, a debt-free balance sheet, successful acquisition integration, strong services backlog, and multiple AI and platform initiatives. The principal challenges were flat total revenue, lower perpetual and services revenue, a decline in gross margin, higher G&A, and uncertainty surrounding SHREWD and the NHS FDP program. Management indicated that the rest of the business remains strong and that these challenges are being offset by other growth initiatives.
View all VHIBF earnings summariesVHIBF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |














